Genmab A/S (GMAB) Expected to Announce Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is expected to be releasing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Genmab A/S to post earnings of $0.47 per share and revenue of $975.4040 million for the quarter. Genmab A/S has set its FY 2025 guidance at EPS.Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 12:00 PM ET.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Genmab A/S Trading Down 0.6%

Shares of GMAB opened at $28.95 on Thursday. The firm has a market capitalization of $18.59 billion, a P/E ratio of 14.55, a P/E/G ratio of 1.61 and a beta of 0.98. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $33.65. The firm has a fifty day moving average price of $29.03 and a 200-day moving average price of $24.02.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of GMAB. Osaic Holdings Inc. increased its holdings in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after acquiring an additional 1,174 shares in the last quarter. Evergreen Capital Management LLC acquired a new position in shares of Genmab A/S during the second quarter valued at about $200,000. Headlands Technologies LLC increased its holdings in shares of Genmab A/S by 551.7% during the second quarter. Headlands Technologies LLC now owns 10,166 shares of the company’s stock valued at $210,000 after acquiring an additional 8,606 shares in the last quarter. Finally, Captrust Financial Advisors increased its holdings in shares of Genmab A/S by 2.4% during the second quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock valued at $464,000 after acquiring an additional 526 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GMAB. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Tuesday, September 23rd. HC Wainwright restated a “buy” rating on shares of Genmab A/S in a report on Monday. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a report on Monday. Zacks Research upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. Finally, Truist Financial lifted their price objective on Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.80.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.